Lifetime classic psychedelic use, particularly tryptamines, may be linked to lower odds for hypertension in the previous year, according to data published in Hypertension.
“The results showed that lifetime classic psychedelic use was associated with a 14% lower odds of hypertension in the past year and that lifetime tryptamine use was associated with a 20% lower odds of hypertension in the past year,” Otto Simonsson, DPhil, from the department of sociology at the University of Oxford, and colleagues wrote. “These findings may prove valuable for understanding the physical health outcomes of classic psychedelic use, with rigorous randomized controlled trials warranted to investigate potential causal pathways of classic psychedelics on blood pressure.”
Psychedelic use and hypertension
For this analysis, researchers utilized data from the National Survey on Drug Use and Health, weighted to be representative of the U.S. adult population, to determine the relationship between lifetime classic psychedelic use and hypertension in the past year.
Published at Fri, 12 Mar 2021 15:39:18 +0000